Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: Effects of vitamin E treatment

Atherosclerosis

Volumn 129, Issue 2, 1997, Pages 169-176

  Mol, Marc J T M ^a   De Rijke, Yolanda B ^a   Demacker, Pierre N M ^a   Stalenhoef, Anton F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antioxidants; atherosclerosis; cytokines; diabetes mellitus; LDL oxidation; smoking; vitamin E

Indexed keywords

ALPHA TOCOPHEROL; CYTOKINE; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LIPID BLOOD LEVEL; LIPID OXIDATION; NORMAL HUMAN; PRIORITY JOURNAL; VOLUNTEER;

ADOLESCENT; ADULT; AGED; CHOLESTEROL; CHOLESTEROL ESTERS; CYTOKINES; DIABETES MELLITUS; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; LIPID PEROXIDATION; LIPIDS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; SIALOGLYCOPROTEINS; SMOKING; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN E;

EID: 0030904025     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)06022-4     Document Type: Article

References (67)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924.
2. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-1792.
3. Ylä-Herttuala S, Palinski W, Rosenfeld ME et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-1095.
4. Boyd HC, Gown AM, Wolfbauer G, Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol 1989;135:815-825.
5. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988;241:215-218.
6. Princen HM, Van Poppel G, Vogelezang C, Buytenhek R, Kok FJ. Supplementation with vitamin E but not beta-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro. Effect of cigarette smoking. Arterioscler Thromb 1992;12:554-562.
7. Reaven PD, Khouw A, Beltz WF, Parthasarathy S, Witztum JL. Effects of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene. Arterioscler Tromb 1993;13:590-600.
8. Reaven PD, Parthasarathy S, Beltz WF, Witztum JL. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arteioscler Thromb 1992;12:318-324.
9. Harats D, Ben-Naim M, Dabach Y, et al. Effect of vitamin C and E supplementation on susceptibility of plasma lipoproteins to peroxidation induced by acute smoking. Atherosclerosis 1990;85:47-54.
10. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, ana animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987;84:5928-5931.
11. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that the antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic (WHHL) rabbit. Proc Natl Acad Sci USA 1987;84:7725-7729.
12. Fruebis J, Steinberg D, Dresel HA, Carew TE. A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J Clin Invest 1994;94:392-398.
13. Kleinveld HA, Demacker PN, Stalenhoef AF. Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 1994;14:1386-1391.
14. Fruebis J, Carew TE, Palinski W. Effect of vitamin E on atherogenesis in LDL-receptor deficient rabbits. Atherosclerosis 1995;117:217-224.
15. DeMaio SJ, King SB, Lembo NJ, et al. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA). J Am Coll Nutr 1992;11:68-73.
16. Steinberg D. Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung and Blood Institute Workshop, September 5-6, 1991, Bethesda, Maryland. Circulation 1992;85:2338-2344.
17. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993:328:1444-1449.
18. Rimm EB, Stampfer MJ, Ascherio A, Giavonucci EL, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in man. N Engl J Med 1993;328:1450-1456.
19. The alpha-tocopherol, beta carotene cancer group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-1035.
20. Hennekens CH, Buring JE. Antioxidant vitamins - benefits not yet proved. N Engl J Med 1994;330:1080-1081.
21. Walldius G, Erikson U, Olsson AG et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-883.
22. Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989;9:567-578.
23. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991;64:5-15.
24. McNally AK, Chisolm GM, Morel DW, Cathcart MK. Activated human monocytes oxidize low-density lipoprotein by a lipoxygenase-dependent pathway. J Immunol 1990;145:254-259.
25. Hiramatsu K, Rosen H, Heinecke JW, Wolfbauer G, Chait A. Superoxide initiates oxidation of low density lipoprotein by human monocytes. Arteriosclerosis 1987;7:55-60.
26. Berliner JA, Territo MC, Sevanian A et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990;85:1260-1266.
27. Thomas CE, Jackson RL, Ohlweiler DF, Ku G. Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. J Lipid Res 1994;35:417-427.
28. Ku G, Thomas CE, Akeson AL, Jackson RL. Induction of interleukin 1 expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadienoic acid. J Biol Chem 1992;267:14 138-14 188.
29. Fong LG, Fong TA, Cooper AD. Inhibition of lipopolysaccharide-induced interleukin-1β mRNA expression in mouse macrophages by oxidized low density lipoprotein. J Lipid Res 1991;32:1899-1910.
30. Hamilton TA, Ma G, Chisolm GM. Oxidized low density lipoprotein suppresses the expression of tumor necrosis factor-α mRNA in stimulated murine peritoneal macrophages. J Immunol 1990;144:2343-2350.
31. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994;14:32-40.
32. Salonen JT, Ylä-Herttuala S, Yamamoto R et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-887.
33. Maggi E, Chiesa R, Melissano G et al. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 1994;14:1892-1899.
34. Puurunen M, Mänttäri M, Manninen V et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154:2605-2609.
35. Lyons TJ. Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabetic Med 1991;8:411-419.
36. Hunt JV, Smith CC, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990;39:1420-1424.
37. Griesmacher A, Kindhauser M, Andert SE et al. Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. Am J Med 1995;98:469-475.
38. Harats D, Ben-Naim M, Dabach Y, Hollander G, Stein O, Stein Y. Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis 1989;79:245-252.
39. Scheffler E, Huber L, Fruebis J, Schulz I, Ziegler R, Dresel HA. Alteration of plasma low density lipoprotein from smokers. Atherosclerosis 1990;82:261-265.
40. Babiy AV, Gebicki JM, Sullivan DR, Willey K. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. Biochem Pharmacol 1992;43:995-1000.
41. Morel DW, Chisolm GM. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J Lipid Res 1989;30:1827-1834.
42. Kleinveld HA, Hak-Lemmers HLM, Stalenhoef AFH, Demacker PNM. Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein. Clin Chem 1992;38:2066-2072.
43. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989;6:67-75.
44. Van de Bovenkamp P, Kosmeijer-Schuil TG, Katan MB. Quantification of oxysterols in Dutch foods: egg products and mixed diets. Lipids 1988;23:1079-1085.
45. Stalenhoef AFH, Kleinveld HA, Kosmeijer-Schuil TG, Demacker PNM, Katan MB. In vivo oxidised cholesterol in atherosclerosis. Atherosclerosis 1993;98:113-114.
46. Van Deuren MJ, Van der Ven-Jongekrijg J, Keuter M, Demacker PNM, Van der Meer JWM. Cytokine production in whole blood cultures. J Int Fed Clin Chem 1993;5:216-221.
47. Drenth JPH, Van Uum SHM, Van Deuren M, Pesman GJ, Van der Ven-Jongekrijg J, Van der Meer JWM. Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-α and IL-1β production. J Appl Physiol 1995;79:1497-1503.
48. Yagi K. Assay for serum lipid peroxide level and its clinical significance. In: Yagi K, (ed). Lipid Peroxides in Biology and Medicine. New York: Academic Press, 1982:223-42.
49. Conti M, Morand PC, Levillain P, Lemonnier A. Improved fluorimetric determination of malonaldehyde. Clin Chem 1991;37:1273-1275.
50. Lehmann J, Martin HL. Improved direct determination of alpha- and gamma-tocopherols in plasma and platelets by liquid chromatography, with fluorescence detection. Clin Chem 1982;28:1829-1843.
51. Demacker PNM, Hijmans AG, Vos-Janssen HE, Van 't Laar A, Jansen AP. A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin Chem 1980;26:1775-1779.
52. Mezzeti A, Lapenna D, Pierdomenico SD et al. Vitamin E, C and lipid peroxidation in plasma and arterial tissue of smokers and non-smokers. Atherosclerosis 1995:112:91-99.
53. Jialal I, Fuller CJ, Huet BA. The effect of α-tocopherol supplementation on LDL oxidation. A dose-response study. Arteriosler Thromb 1995;15:190-198.
54. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994;43:1010-1014.
55. Gugliucci A, Menini T, Stahl AJ. Susceptibility to copper-enhanced autooxidation of VLDL+LDL fractions from diabetic patients. Biochem Mol Biol Int 1994;32:139-147.
56. Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 1994;94:771-778.
57. Scheffler E, Wiest E, Woehrle J et al. Smoking influences the atherogenetic potential of low-density lipoprotein. Clin Invest 1992;70:263-268.
58. Hodis HN, Crawford DW, Sevanian A. Cholesterol feeding increases plasma and aortic tissue cholesterol oxide levels in parallel: further evidence for the role of cholesterol oxidation in atherosclerosis. Atherosclerosis 1991;89:117-126.
59. Carpenter KLH, Taylor SE, Ballantine JA, Fussell B, Halliwell B, Mitchinson MJ. Lipids and oxidised lipids in human atheroma and normal aorta. Biochim Biophys Acta 1993;1167:121-130.
60. Smith LL, Johnson BH. Biological activities of oxysterols. Free Radic Biol Med 1989;7:285-332.
61. Peng SK, Taylor CB, Hill JC, Morin RJ. Cholesterol oxidation derivatives and arterial endothelial damage. Atherosclerosis 1985;54:121-133.
62. Ramasamy S, Biossonneault GA, Hennig B. Oxysterol-induced endothelial cell dysfunction in culture. J Am Coll Nutr 1992;11:532-538.
63. Morin RJ, Peng SK. The role of cholesterol oxidation products in the pathogenesis of atherosclerosis. Ann Clin Lab Sci 1989;19:225-237.
64. Wiklund OV, Mattsson L, Liu Y. Oxysterols in atherosclerotic tissue may regulate macrophage functions. Circulation 1995;92:1-289.
65. Theunissen JJ, Jackson RL, Kempen HJ, Demel RA. Membrane properties of oxysterols. Interfacial orientation, influence on membrane permeability and redistribution between membranes. Biochim Biophys Acta 1986;860:66-74.
66. Van Deuren M, Van der Ven-Jongekrijg J, Demacker PNM et al. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 1994;169:156-161.
67. Barrera P, Haagsma CJ, Boerbooms AMT et al. Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 1995:34:747-755.